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Theprinciplesofopenversuslasermicrosurgicalapproachesforpartial
resections of the larynx are described, oncologic as well as functional
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resultsdiscussedandcorrespondingoutcomesfollowingprimaryradio-
therapy are opposed. Over the last decade, the endoscopic partial re-
section of the larynx has developed to an accepted approach in the 1 Department of
Otorhinolaryngology – Head treatment of early glottic and supraglottic carcinomas thus leading to
and Neck Surgery, Christian- aremarkabledeclineintheuseofopensurgery.Comparingthevarious
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surgical approaches of laryngeal partial resections, the oncological
outcome of the patients, as far as survival and organ preservation are
concerned,arecomparable,whereasfunctionalresultsoftheendoscop-
ic procedures are superior with less morbidity. The surgical procedures
put together, are all superior to radiotherapy concerning organ preser-
vation. Transoral laser microsurgery has been used successfully for
vocal cord carcinomas with impaired mobility or fixation of the vocal
cord, supraglottic carcinomas with infiltration of the pre- and/or para-
glottic space as well as for selected hypopharyngeal carcinomas. It has
been well documented that laser microsurgery achieves good oncolo-
gical as well as functional results with reasonable morbidity. However,
patients with those tumours have been successfully treated by open
partial resections of the larynx at medical centres with appropriate ex-
pertise.Theinitiallyenthusiasticassessmentofstudyresultsconcerning
the efficacy of various protocols of chemoradiation with the intent of
organ preservation for laryngeal and hypopharyngeal carcinomas are
judged more cautious, today, due to recent reports of rather high rates
of late toxicity complications.
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preservation, partial laryngectomy, transoral laser microsurgery,
chemoradiation
1. Introduction
During the last 10 years the treatment options for laryn-
geal and hypopharyngeal cancer have changed signifi-
cantly. The development of transoral laser microsurgery,
improvements in delivery of radiation therapy and the
advent of new radiation protocols with or without
chemotherapyhavesupplementedthepreviousstandard
techniques of open partial laryngectomy, total laryngec-
tomy,andradiotherapy.Althoughnodefinitiveconclusions
have been reached with regard to the role of these new
treatment modalities, the importance of organ preserva-
tionandqualityoflifeissueshavebecomeamajorfactor
in decision-making and therapy planning.
With open partial laryngectomy, transoral laser microsur-
gery and radiation therapy with or without chemotherapy
are methods available which stand for preservation of
the larynx. This review focuses on the treatment of previ-
ously untreated tumors. The description of surgical pro-
cedures intends to describe anatomical structures and
the basic surgical principles. This review neither intends
toreplaceasurgicaltextbooknordoesitprovidecompre-
hensive surgical instructions. Experimental therapies
suchasphotodynamictherapy,theuseofphotoangiolytic
lasers,robot-assistedsurgery,andtheuseofchemother-
apy as a single modality treatment are not discussed in
this review.
Theauthorsofthisarticlereviewanddiscusstherelevant
studies of the last decade with respect to oncologic
treatment outcomes, morbidity, larynx preservation, and
organ function.
2. Early Glottic Carcinomas
2.1 Definition
Approximately 3400 laryngeal cancers are newly diag-
nosed in Germany each year. Sixty per cent are glottic
carcinomas of which 50% are detected as early stage
tumors. Therefore, treatment of early glottic carcinomas
is still of highly important and relevant. Treatment goals
1/31 GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2011, Vol. 10, ISSN 1865-1011
Review Article OPEN ACCESSare to achieve local tumor control and preservation of
the larynx with best possible function.
There is no generally accepted definition for the term
“early” glottic cancer. While some authors believe that
this definition includes premalignant changes (severe
dysplasia), others classify T1 tumors as early glottic car-
cinomas, and some even include T2 lesions in this cat-
egory.Inaccordancewiththecurrentliteraturewedefine
early glottic cancer as carcinoma in situ (Tis), non-meta-
stasizing tumors involving one (T1a) or both (T1b) vocal
cords as well as unilateral or bilateral glottic carcinomas
with infiltration of the supra- and/or subglottis with pre-
servation of vocal cord mobility (T2a).
2.2 Special Diagnostic Aspects
Laryngoscopy with adequate documentation is still the
most valuable diagnostic tool. Irrespective of later treat-
ment, a tissue diagnosis has to be performed to verify a
vocal cord proliferation’s malignancy. Routine CT scans
of early glottic carcinomas are generally not indicated; in
carcinomas of the anterior commissure they may be
consideredhelpful.CTscansshouldalwaysbeperformed
in patients with recurrent tumors.
Histopathologic examination of a biopsy specimen by
microlaryngoscopy is still the diagnostic gold standard.
It is well known, that a significant number of biopsies in
early glottic cancer patients result in complete tumor ex-
cision. Stutsman and McGavran [1] observed as early as
in 1971 that after preceding biopsy from the vocal cord
no residual carcinoma could be found in 13 out of 60
hemilaryngectomy specimens.
Steiner’s group reported that in 126 (49%) of 253 pa-
tientswithT1aglotticcarcinomaadiagnosticmicrolaryn-
goscopy with biopsy was performed prior to admittance
elsewhere. In 39 (31%) patients no residual carcinoma
was found in the laser resection specimen although clin-
ical examination showed tissue proliferations suspicious
for malignancy. Similar results were reported by Nassif
et al. [2] who found 33% (5 out of 15) resection speci-
mens to be free of tumor after previous biopsy. These
results show that a significant number of patients are
inevitably overtreated when radiotherapy is the standard
treatment protocol. This poses an unjustifiable risk of
overtreatment to early glottic cancer patients.
2.3 Open Partial Laryngectomy
There are various surgical procedures for the treatment
of early glottic cancer, including open cordectomy via
medial thyrofissure, open vertical partial laryngectomy,
hemilaryngectomy(inselectedcases)andtransorallaser
microsurgery.
With cordectomy via thyrofissure and open vertical
(frontolateral) partial laryngectomy a horizontal midline
skin incision along the tension lines is performed. After
dissection of the strap muscles the thyroid cartilage is
exposed and split vertically in the midline or paramedian
down to the inner perichondrium. Following the incision
ofthecricothyroidmembraneandinspectionofthetumor,
the soft tissues of the larynx are incised and the vocal
fold is removed adapted to the extent of the lesion. If the
tumor infiltrates the anterior commissure, a small part
of the contralateral vocal fold is removed additionally.
With open vertical partial laryngectomy the entire vocal
fold together with a part of the thyroid cartilage is resect-
ed. The size of the cartilage window is defined by tumor
extent.Incarcinomasoftheanteriorcommissure,abilat-
eral paramedian incision of the thyroid cartilage is per-
formed and the cartilage resected together with the an-
terior part of both vocal cords. Pedicled flaps from the
ventricular fold can be used to reconstruct the defect. In
comparisontotransorallasermicrosurgerythemorbidity
of open vertical partial laryngectomy is higher due to the
need of temporary tracheostomy and a higher rate of
postoperative wound infections.
Supracricoidpartiallaryngectomywithcricohyoidoepiglot-
topexie (SCPL-CHEP) involves the resection of both vocal
folds, both ventricular folds, the paraglottic tissues bilat-
erally, the entire thyroid cartilage, the petiole of the epi-
glottis, and the lower portion of the preepiglottic fat. For
reconstruction, the cricoid cartilage is first attached to
the epiglottic remnant and then to the hyoid bone. This
operation always requires temporary tracheostomy and
nasogastric tube feeding.
With transoral laser microsurgery the vocal folds are ex-
posedwithalaryngoscopeintheintubatedpatient.Small
midcordal tumors can be resected en bloc. More extens-
ivevocalcordlesionsareremovedpiecemealwithaclear
margin of approximately 1–3 mm [3]. We try to maintain
narrow margins and preserve as much healthy tissue as
possibletoimprovetheprospectsforpostoperativevoice
rehabilitation. Postoperative voice function is mainly in-
fluencedbytheamountoftissueresected.Figure1shows
the histological structure of the vocal fold and its neigh-
boring tissues. Morbidity associated with transoral laser
microsurgeryofearlyglotticcancerislow.Atracheostomy
is never required and complications are rare, enabling
the surgery to be performed on an outpatient basis [4].
The resection of larger glottic carcinomas with impaired
vocal cord mobility by laser microsurgery requires sub-
dividing the tumor into several parts. Tumors that have
invadedtheparaglotticspacearesubdividedbyincisions
extending laterally to the thyroid cartilage and inferiorly
to the cricoid cartilage (Figure 2). The resection can be
extended to the perichondrium of thyroid and cricoid
cartilage, to thyroid and cricoid cartilages themselves, to
the arytenoid cartilage, the cricothyroid membrane and
theextralaryngealsofttissues.Atracheostomyisseldom
necessary and postoperative complications are rare.
2.3.1 Special Aspects of Histopathologic
Examination of Surgical Specimens
The tissue effects of surgical carbon dioxide lasers used
today have been substantially improved by more precise
focusing techniques. The zone of charring and edema
measures only 25 µm and does not affect the assess-
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Ambrosch et al.: Functional organ preservation in laryngeal and hypopharyngeal ...Figure 1: Left: Histologic coronal section of an adult larynx. Specimen: P. Steven. Photograph: B. Tillmann. Stain:
Orcein-Pikroindigokarmin. From B. Tillmann, 2010 [262]. Right: Histologic coronal section through the vocal fold of an adult.
Specimen: B. Tillmann. Stain: Elastica. From B. Tillmann, 2010 [262].
Figure 2: Bony and fibroelastic structures of the larynx. Axial view. Specimen of the scientific collection of the Inst. of Anatomy
of CAU Kiel, Photograph: B. Tillmann. From B. Tillmann, 1997 [263]. The dotted lines show the resection in a case of advanced
vocal cord carcinoma with resection of the vocal fold, the false cord and the arytenoid cartilage.
abilityofevensmallspecimens[5].Artifactsandnecrosis
due to tissue squeezing or coagulation diathermy seem
to have a bigger impact on the assessability.
Today narrow safety margins are widely accepted in
laryngeal surgery [3], [6]. If a surgical margin is found to
be positive for tumor cells by histopathology, the re-ex-
cision of further tissue is indicated to remove or rule out
anyresidualtumor.Thisapproachseemstobethesafest
method even though more tissue is lost and in principle
atumorrecurrencecanbetreatedsuccessfullybyalater
endoscopic excision, assumed, that the recurrence is
detected early [7].
Sincere-excisionspecimensoftenaretumorfree[7]and
the glottis is easily inspected by laryngoscopy, it is dis-
cussed whether frequent follow up exams are sufficient
in these cases. Preuss et al. [8] reported on positive re-
sectionmarginsin84(46%)of181patientsafterenbloc
resection of T1 and T2 glottic carcinomas. In 55 patients
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ofthere-resectionspecimenswerepositive.Otherauthors
haveseensimilarresultsinsmallerstudies[9],[10],[11],
[12]. In our view a "wait and watch" policy should only be
chosen, if the patient was fully informed about the pros
and cons.
2.3.2 Classification of Endolaryngeal
Cordectomy
During the last couple of years various classification sys-
tems of endolaryngeal laser resections were proposed
[13], [14]. In 2000 Remacle et al. [15] published a clas-
sification proposal on behalf of the European Laryngolo-
gicalSociety,whichisnowwidelyaccepted.Eightdifferent
types of endoscopic cordectomies are divided according
to the extent of the resection. These classifications are
useful with regard to comparability of treatment out-
comes.
2.4 Oncologic Results
2.4.1 Preliminary Remarks
Thebestsuitedtreatmentmodalityforearlyglotticcancer
is still under debate. A series of retrospective and pro-
spective non-controlled studies have shown that both
primary surgery and radiotherapy are effective methods
in treating glottic carcinomas. Recently, two randomized
studies have been initialized to compare transoral laser
microsurgery and primary radiotherapy with regard to
oncologic results, morbidity, voice quality, complications
andcost[16],[17].Theimplementationoftheprospective
randomized EaStER study (Early Stage glottic cancer:
Endoscopic excision versus Radiotherapy; Chief Investi-
gator Prof. M. Birchall) was recommended in the UK in
2004 by the CRUK (Cancer Research UK) under the pre-
condition of a successful preliminary feasibility study.
Due to failure in recruiting enough patients for random-
ization (most patients or physicians preferred one of the
two treatment modalities) the study had to be stopped
in 2009. Another randomized study, conducted by
Prof. W. Coman in Brisbane, Australia, could not be
completed due to similar reasons [17].
Essential for evaluating the efficacy of a treatment mo-
dalityforearlyglotticcancerarethefollowingparameters:
Local control and larynx preservation, complications und
undesirable side effects of treatment, treatment options
for recurrences, functional results, and the cost. Survival
rates do not play a major role for the evaluation of the
efficacy, because the risk of death due to a second
primary lung cancer is considerably higher than due to
early glottic cancer.
2.4.2 Results of Open Vertical Partial
Laryngectomy
Duringthe70iesand80iesearlyglotticcarcinomaswere
surgically treated by open vertical partial laryngectomy
(cordectomy via laryngofissure, frontolateral partial
laryngectomy, and in selected cases hemilaryngectomy).
Inthepasttwodecadesthereisadeclininguseofvertical
partial laryngectomy. This is reflected by a decreasing
number of reports published in the current English liter-
ature.
In 1994, Thomas et al. [18] reported a series of 159 pa-
tientswithT1glotticcancerwhounderwentverticalpartial
laryngectomyattheMayoClinicbetween1976and1986.
The 5-year local control rate was 93% and in 94% of the
patients, the larynx could be preserved. Spector et al.
[19] treated 404 patients with T1 glottic cancer with a
5-year local control rate of 92% and larynx preservation
rate of 93%. In 71 patients with T2 glottic carcinoma the
5-yeardisease-specificsurvivalratewas92%.Thelarynx
preservation rate was 92% [20]. Brumund et al. [21] de-
scribe the treatment results of vertical partial laryngec-
tomy in 232 patients with T1 and 35 patients with T2
vocal cord carcinomas. The 5-year local control rate was
91% and 68.7%, respectively. In 92.9% and 93.3% the
larynxwaspreserved.Overall18.1%ofpatients,however,
sufferedfrompostoperativecomplicationssuchaswound
infection (7%) or subcutaneous emphysema.
Crampette et al. [22] report on 81 patients with early
glottic carcinomas treated with a modified subtotal
laryngectomy with cricohyoidoepiglottopexy. No local re-
currenceswhereobservedinT1cancerpatientswhereas
the 5-year local control rate in T2 cancer patients was
92%. Although the postoperative clinical course was un-
eventful, all patients showed remarkable voice impair-
ment. Makeieff et al. [23] assessed the voice related
quality of life using the Voice Handicap Index [24] in 64
patientswithT1borT2glotticcarcinomawhounderwent
supracricoid partial laryngectomy. Fifty-five per cent of
workingpatientswereunabletopracticetheirprofession
or had to change their job due to voice impairment.
Itcanbeconcludedthatopenverticalpartiallaryngectomy
inearlyglottictumorsdemonstratesveryfavorableonco-
logic results. In patients with T1 glottic cancer the local
control rate averages between 92%–100% with a laryn-
geal preservation rate between 94%–100%. In patients
withT2glotticcancerwithunimpairedvocalcordmobility
localcontrolratesaveragebetween69%–93%andorgan
preservation rates between 92%–93%.
2.4.3 Results of Transoral Laser Microsurgery
In 1993, Steiner [25] reported a first series of 240 pa-
tients who underwent transoral laser microsurgery for
carcinomas of the larynx between the years 1979 and
1991.Amongthe240patientswere159withearlyglottic
carcinomas (Tis 29, T1 96, T2a 34). Only 6% developed
a local recurrence with only one patient requiring a total
laryngectomy. Since Steiner’s pioneering work transoral
laser microsurgery has become a widely accepted and
successfully used method in treating early laryngeal
cancer.Inrecentyearsithasbecomeastandardmethod
for the treatment of early vocal cord cancer [26], [27].
Steiner’s group from Göttingen/Germany published a
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series of papers in the following years focusing on the
oncologicresultsinearlyglotticcancer.TheKaplan-Meier
5-year local control rate for pT1a carcinomas (n=248)
was 92%, for pT1b carcinomas (n=35) 80% and for pT2a
carcinomas (n=109) 84%. Secondary laryngectomy was
performed in 1.2% of patients with pT1a, in 5.7% with
pT1b, and in 3.7% with pT2a carcinomas. The Kaplan-
Meier5-yearultimatelocalcontrolratewas99%forpT1a,
97% for pT1b, and 98% for pT2a carcinomas [28].
Many authors have published recently on transoral laser
microsurgery in patients with Tis-T2a glottic cancer
demonstrating good oncologic and functional results. An
overview of the literature of the last 10 years is shown in
Table 1 and Table 2. Karatzanis et al. [29] compared
transoral laser microsurgery and open partial laryngec-
tomy in two cohorts of patients with T1a and T1b glottic
cancer treated at the University of Erlangen/Germany.
Local control rate and disease specific survival rate
showednosignificantdifferencebetweenthetwocohorts.
In conclusion it can be stated that with transoral laser
microsurgery the 5-year local control rate for T1 glottic
cancer is 85%–96% with a larynx preservation rate of
94%–99% (Table 1). For T2 glottic carcinomas the 5-year
local control rate is 66%–84% and the 5-year larynx pre-
servation rate 83%–96% (Table 2). The tumor-related
death rates are <1% for T1 and <3% for T2 carcinomas.
2.5 Early Glottic Carcinomas with
InvolvementoftheAnteriorCommissure
Inearlyglotticcarcinomaswithinvolvementoftheanterior
commissure the special anatomy of this region is of clin-
ical importance. The absence of perichondrium at the
vocal ligament insertion, the extension of the vocal liga-
mentfibersintothethyroidcartilage,andtheconnections
between the intra- and extralaryngeal blood vessels and
lymphatics[30],[31],[32](Figure3,Figure4)wereoften
referred to as possible reasons for recurrences in the
anterior commissure. Kirchner and Carter [33] observed
in serial organ sections that T1a and T1b carcinomas
rarely infiltrate the thyroid cartilage. On the other hand,
carcinomasoftheanteriorcommissurethathaveinvaded
the cartilage typically show supraglottic extension to the
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Left inferior: Histologic horizontal section through an adult larynx at the plane of the anterior commissure. Stain: Goldner.
Specimen: B. Tillmann.
Right: Laryngeal skeleton with blood vessels. Corrosion specimen of the scientific collection of the Inst. of Anatomy of CAU Kiel,
Klaws fecit. Photograph: B. Tillmann.
petiolearea,subglotticextension,orboth(T2carcinomas)
[33], [34]. In a recent study by Hartl et al. [35] these
findingscouldbeconfirmed.Thehistopathologicexamin-
ationof358resectionspecimensfromthelarynxshowed
in only 8.9% cancer infiltration of the thyroid cartilage.
Thestudyrevealed,thattheinfiltrationrateofthethyroid
cartilage was the same for both glottic carcinomas with
and without involvement of the anterior commissure. In-
filtrationofthethyroidcartilagecorrelatedwithTcategory
and vocal cord mobility.
Figure 4: Histologic horizontal section through an adult larynx
at the insertion of the vocal ligaments at the anterior
commissure. Stain: Gomori. Specimen: F. Paulsen and B.
Tillmann. From Paulsen F, Tillmann B, 1996 [30].
2.5.1 Results with Involvement of the Anterior
Commissure
Involvement of the anterior commissure means always
achallengeforanysurgicaltreatment[36]whereasmost
authorsagreethatitdoesnotaffecttheresultsofprimary
radiotherapy[37],[38],[39],[40].Laccourreyeetal.[41]
reportedon416patientswithT1andT2glotticcarcinoma
who underwent open vertical partial laryngectomy. The
local recurrence rate in carcinomas with involvement of
the anterior commissure was 23%. As an alternative to
frontolateral partial resection supracricoid laryngectomy
wasperformedinsomecenterswiththeintenttoimprove
thelocalcontrolrateinanteriorcommissurecarcinomas.
Laccourreye et al. [42] reported on 62 cases of
SCPL-CHEP in T1 and T2 glottic carcinomas with anterior
commissure involvement. Eighty-one per cent of the pa-
tients had undergone neoadjuvant chemotherapy prior
to surgery. An excellent 5-year local control rate of 98%
could be achieved. No total laryngectomy or permanent
tracheotomyhadtobecarriedoutforfunctionalreasons.
One must take into consideration however, that
SCPL-CHEP with prior chemotherapy is associated with
considerable morbidity and can be applied not to every
patient. Even though all patients could be decannulated
inLaccourreye’sseries,17patientsneededpostoperative
swallowing training, 4 received a temporary and one a
permanent PEG feeding tube. Patients after SCPL-CHEP
develop compensatory supraglottic phonation mechan-
ismsresultinginmoderatetoseveredysphonia[43],[44],
[45].
Steiner et al. [46] analyzed the influence of anterior
commissure involvement on local recurrences, laryngeal
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preservation, and survival in 263 patients with early
glottic cancer who underwent transoral laser microsur-
gery. It was shown that involvement of the anterior com-
missureaffectedthelocalcontrolandorganpreservation
rates but not the survival rates. The Kaplan-Meier 5-year
local control rate of carcinomas with or without involve-
ment of the anterior commissure was 86% vs. 95% for
T1a carcinomas, 75% vs. 93% for T1b carcinomas and
78% vs. 83% for T2a carcinomas. Larynx preservation
was possible in 93% vs. 99% of T1a cancer patients, in
88% vs. 94% in T1b cancer patients and 93% vs. 97% in
T2a cancer patients. These results could be confirmed
in a subsequent study encompassing 444 patients [47].
Similar results were found by Sachse et al. [48] in a
retrospective study. Those authors reported poorer local
controlratesinT1andT2glotticcarcinomaswithinvolve-
ment of the anterior commissure than in carcinomas
without. No differences were found, however, comparing
open vertical partial laryngectomy and transoral laser
microsurgery. In contrast, Chone et al. [49] and Peretti
et al. [50] did not find significantly different local control
ratesinlasermicrosurgicallytreatedearlyglotticcancers
with or without anterior commissure involvement.
Herranz et al. [51] in a literature review have analyzed
and summarized the treatment results in early glottic
cancerwithinvolvementoftheanteriorcommissure.They
conclude that the three treatment options (surgery open
or endoscopic, radiotherapy) have similar outcomes. The
choice of treatment should be based on the experience
and skill of the treating physician. With transoral laser
microsurgery it is of importance to gain good exposure
of the tumor and to keep sufficient surgical radicality in
order to prevent local recurrence. In difficult cases a fol-
low-up microlaryngoscopy after 6–8 weeks in the sense
of a “second look” operation can be useful to rule out
any residual tumor [3], [7].
2.6 Results of Radiotherapy
Within the last 50 years primary radiotherapy was used
to treat early glottic cancer patients as an alternative to
surgery. Due to good local control rates, disease-specific
survival rates, good long-term function of the upper
aerodigestive tract (voice and swallowing function), and
thenon-invasivenatureofthemethod,primaryradiother-
apy was considered to be the gold standard in Northern
America,ScandinaviaandtheUK.Therapycanbecarried
out on an outpatient basis and lasts for 4–6 weeks.
Table 3 and Table 4 show an overview of the literature
of the last decade. Regarding the oncologic results it can
be summarized, that 5-year local control rates between
82% and 93% in T1 carcinomas and laryngeal preserva-
tion rates of 89%–96% have been achieved (Table 3). In
T2 carcinomas 5-year local control rates vary between
57%and80%withlarynxpreservationratesof73%–82%
(Table 4). The TNM-related death rate is about 1%–4%
for T1 carcinomas and 4%–9% for T2 carcinomas.
By comparison with transoral laser microsurgery, it be-
comes evident that primary radiotherapy is associated
withonaveragelowerlocalcontrolrates,highernumbers
ofsecondarylaryngectomy,andsubstantiallyhigherTNM-
related deaths. Although routine post-treatment follow-
up is generally performed for early detection of recur-
rences, the poorer results of primary radiotherapy are
due to a much more difficult clinical assessment of the
larynxafterradiotherapythanaftersurgery.Radiotherapy
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cannot be repeated which limits therapeutic options in
caseofrecurrenceorasecondprimarytumorinthehead
and neck region. In most cases of local recurrence or re-
sidual tumor total laryngectomy is needed. About
11%–13% of patients treated with primary radiotherapy
for early glottic cancer have to undergo secondary laryn-
gectomy.
Thurnher et al. [52] published the only study comparing
all three therapy options for early glottic carcinoma.
Transoral laser microsurgery, open vertical partial laryn-
gectomy and primary radiotherapy were performed on
3 different cohorts of patients T1 vocal cord cancer at
the Vienna University Hospital. Primary radiotherapy had
significantlylowerlocalcontrolratesanddisease-specific
survival rates than the two surgical approaches, with
transoral laser microsurgery offering the best overall
results.
2.7 Complications
Thepublishedliteraturedemonstratesthatcomplications
after transoral laser microsurgery are rare and amount
to less than 1%. Late complications do not occur. The
complication rate of primary radiotherapy is also low.
Severe complications such as chondronecrosis occur in
lessthan1%ofT1carcinomastreatedwithprimaryradio-
therapy [37], [38], [40], [53]. Following radiotherapy of
T2 carcinomas, complication rates between 2% and 4%
have been reported [37], [54], [55].
2.8 Functional Results
There is consensus that since the introduction of
transoral laser microsurgery for the treatment of early
glottic cancer, the voice quality has improved compared
to open cordectomy via laryngofissure [56]. Post-treat-
ment voice quality was evaluated in a number of studies
comparing transoral laser microsurgery with primary ra-
diotherapy [57], [58]. Some of those studies found no
difference in voice quality whereas others state better
results after radiotherapy [59], [60].
Several recent studies comparing quality of voice after
laser microsurgery and radiotherapy noted that despite
different patient selection and methods of voice analysis
(perceptive voice analysis, use of semi objective scales
or quantitative acoustic measurements) similar voice
resultswereachievedwithbothtreatmentmethods[61],
[57], [62], [63].
With the different methods of voice analysis, important
parameters to assess voice quality objectively can be re-
corded.Theobjectivevoicequalityandtheself-perception
of a voice handicap can differ significantly. The Voice
Handicap Index (VHI) was developed to document the
patient’sself-perceptionofvoicequality[24].VHIanalysis
done by Nunez Batalla et al. [62] showed that patients
withT1vocalcordcancerperceivedlittlenegativeimpact
on their voice after transoral laser microsurgery or radio-
therapy. In addition to acoustic parameters and the VHI
for self-assessment Loughran et al. [63] evaluated voice
qualitybyusingtwootherinstruments,theVocalPerform-
ance Questionnaire (VPQ) and the Voice Symptom Score
(VoiSS).Nosignificantdifferencesbetweentransorallaser
microsurgery and radiotherapy were found.
In2006,Cohenetal.[64]reportedtheresultsofameta-
analysis of 6 studies on voice-related quality of life in
patientswithT1glotticcancertreatedwithprimaryradio-
therapy or transoral laser microsurgery. The VHI scores
of 208 patients after transoral laser microsurgery and of
91patientsafterradiotherapyweresimilarlylow,suggest-
ing little influence of both treatment modalities on voice-
related quality of life.
In our clinical experience, postoperative voice quality is
influenced by several factors. Of particular importance
arebothlocationandsuperficialextensionandthedepth
of tumor invasion. These parameters determine the
minimum extent of an oncologically sound tumor resec-
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safety margins the surgeon chooses and whether the re-
section includes the anterior commissure [7], [65], [66].
Finally,voicequalityisdeterminedbyanindividualwound
healingprocess,whichisassociatedwithvaryingdegrees
ofgranulationtissueandpostoperativescarring.Effective
postoperative voice therapy is another important factor.
The prospects of successful voice rehabilitation depend
ultimately on what functionally important structures the
surgeon was able to preserve. These prospects are most
favorablewhenthevoicecanberehabilitatedatthelevel
of glottic phonation [67].
2.9 Surgical Voice Rehabilitation
Asmentionedabovemostpatientsaresatisfiedwiththeir
voice after transoral laser microsurgery. However, en-
dolaryngeal cordectomy often does result in dysphonia
due to glottic insufficiency because of loss of tissue or
scar formation, reducing vocal ability. Postoperative dys-
phonia is characterized by breathiness, roughness, as-
thenicity(auditiveimpressionofweakness,hypofunctional
voice) or strain (auditive impression of excessive tension
associated with phonation), leading to the patient’s de-
mand for further treatment. Voice therapy seems to be
sufficientformostpatients.Insuitedcasessurgicalvoice
rehabilitation might be considered. Voice rehabilitation
surgery should not be performed earlier than 6–12
months after tumor resection in order to wait for the final
result of scar formation. The goal of the operation is to
medialize the vocal fold to close the glottic gap and
therefore improve voice quality.
Superficial scars involve Reinke’s space and the vocal
ligament.Theepitheliummustbefreedfromtheligament
and a pouch is created. After implantation of autologous
fattytissuethepouchisclosedbysutures[68],[69],[70],
[71], [72]. As with sulcus-vergeture management is diffi-
cult. Smaller defects due to partial cordectomy involving
thevocalligamentandthevocalismusclecanbetreated
withmedializationsurgery.Inmostcasesthesurgeryhas
to be combined with the injection of collagen or autolog-
ous fatty tissue [73]. In selected cases injectable materi-
als(e.g.Polydimethylsiloxan,VoxImplant®)canbeofuse
[74]. Bigger defects due to complete or extended
cordectomyareoftendifficulttotreat.Scarsinvolvingthe
perichondrium and the thyroid cartilage are difficult to
detachwithoutperforatingthepouchinwhichacartilage
strut is positioned [73], [74], [75]. In cases of tumor re-
sectionsincludingtheperichondrium,laryngealframework
medializationmaybeunsuccessful.Thosepatientsshould
receive voice therapy with the aim to train supraglottic
voice production.
Anterior glottic webs are inevitable after resection of an-
teriorcommissurecarcinomas.Thinandsuperficialwebs
often cause no or only mild dysphonia and do not need
furthertreatment.However,extensivescarringmayresult
in severe dysphonia and dyspnea. The exact thickness
of the web can be determined by microlaryngoscopy
combined with 0°-, 45°-, and 70° telescopes. Thin and
small webs are excised with the CO2 laser. To prevent
reformation of the web, the anterior commissure is
treated locally with Mitomycin-C (1 mg/ml) to inhibit pro-
liferation of fibroblasts [76], [77]. If extensive fibrin ex-
sudation and granulation tissue formation are seen
postoperatively,anothermicrolaryngoscopywithremoval
of granulation tissue and re-application of Mitomycin-C
is advisable after 2 weeks. Webs that extend to the sub-
glottis or recurrent webs after resection and Mitomycin-
C application can be successfully treated by endoscopic
scar resection and fixation of a silicon sheet or keel in
the anterior commissure as described by Lichtenberger
[78].
2.10 Cost of Therapy
Due to increasing importance of economic aspects of
differenttreatmentmodalities,severalcostanalyseshave
beenperformed.Accordingtomostanalyseslasermicro-
surgerycostslessthanradiotherapy[79],[80],[81].Laser
microsurgery may dominate radiotherapy from a cost-
utility standpoint because lesser resources are needed
for salvage treatment.
2.11 Conclusion
Thecomparisonoftreatmentresultsoflasermicrosurgery
and open vertical partial laryngectomy in early glottic
cancer shows that local control and disease-specific
survival do not differ. Transoral laser microsurgery has
widelyreplacedopensurgeryduetolessmorbidity,better
voice quality and lower cost. Accordingly, no articles on
open surgery for early glottic cancer could be found in
the English literature in the last 10 years.
Today, laser microsurgery is an established method not
only for midcordal carcinomas but for all early glottic
carcinomas.Wedonotregardinvolvementoftheanterior
commissure to be a contraindication for laser microsur-
gery because of comparable local control rates for both
lasermicrosurgeryandopenverticalpartiallaryngectomy.
WithSCPL-CHPexcellentlocalcontrolratesareachieved,
however, it comes with the price of a higher morbidity
and often severe impairment of voice and swallowing
function.Theliteratureofthepast10yearsrevealedthat
SCPL-CHPisperformedonselectedpatientsinonlyafew
centers around the world.
Comparing radiotherapy to surgical therapy with regard
to local control, larynx preservation and disease-specific
survival surgical treatment is superior. The voice out-
comes after laser microsurgery and radiotherapy are
comparable.
Eventhougharandomizedstudycouldnotbecompleted,
the current literature allows the conclusion that laser
microsurgery is the method of choice – highly accepted
by the patient – for the treatment of early glottic cancer
with regard to oncologic, functional, and economic as-
pects.
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Mobility or Fixation of the Vocal
Cord
3.1 Definition
T2 glottic carcinomas comprise a very heterogeneous
group of tumors. Some tumors show supra- and/or sub-
glottic tumor extension with normal vocal cord mobility,
whileotherscauseimpairedvocalcordmobilityandshow
considerablesupra-and/orsubglotticextension.Thetwo
groups differ markedly in their prognosis. T2 tumors with
impairedvocalcordmobilityarecomparabletoT3tumors
with vocal cord fixation with respect to local control and
survival.
3.2 Special Diagnostic Aspects
Beside routine laryngoscopy for the assessment of mor-
phologyandvocalcordmobility,CTorMRIscansoflarynx
andneckshouldbedoneforpreoperativestaging.Extens-
ive tumor infiltration into thyroid or cricoid cartilage or
into the soft tissue of the neck is a contraindication for
partial laryngectomy. While infiltration to the soft tissue
of the neck is usually easily detected by imaging techno-
logy, the diagnosis of thyroid cartilage erosion can be a
challenge. In a meta-analysis published by Yousem and
Tufano [82] sensitivity and specificity of thyroid cartilage
infiltrationwereestimatedtobe92%and79%formagnet
resonance imaging and 64% and 89% for computed
tomography.
3.3 Oncologic Results
3.3.1 Results of Transoral Laser Microsurgery
In 2001, Steiner’s group reported the results of laser
microsurgeryfor167glotticcancerpatientswithimpaired
vocal cord mobility (T2b) or fixation (T3) [28]. Ninety-
seven patients were classified as pT2b(p)N0M0 and 70
patientsaspT3(p)N0M0.Forty-fivepercentofpT3tumors
showedfixationofthearytenoidcartilage.Adjuvantradio-
therapy was performed in 10.3% of stage II and in 8.6%
ofstageIIIpatients.TheKaplan-Meier5-yearlocalcontrol
rate was 74% for pT2b carcinomas and 68% for pT3
carcinomas. Secondary laryngectomy was carried out in
13.4% and 14.3%, respectively. The 5-year ultimate local
control rate was 87% and the 5-year disease-specific
survival rate was 62% in both groups.
Postoperative voice quality was satisfying in the majority
of patients despite the extensive partial laryngeal resec-
tions.Speechintelligibilityinthetelephonetestwasmore
than 90% for both groups. One patient developed a glot-
tic/subglottic stenosis and has a permanent tracheo-
stoma. No tracheotomies were done together with the
transoral laser resections of the primary tumors. Only
11% of the stage II patients and 44% of the stage III pa-
tients needed a nasogastric feeding tube for a median
time period of 4 or 5 days, respectively; all the other pa-
tientsdidn’tneedtubefeeding.Allpatientsfullyrecovered
and regained normal swallowing function. In summary,
with primary laser microsurgery in 70% of patients with
pT2bandpT3carcinomas,long-termlocoregionalcontrol
with preservation of a functional larynx was achieved at
an overall low morbidity.
Little data on results of laser microsurgery in more ad-
vanced glottic carcinomas are to be found in the current
literature. Motta et al. [83] reported on 37 patients with
T3 glottic carcinomas, they treated with laser microsur-
gery.Fifty-fivepercentofpatientsdevelopedlocoregional
recurrences and in 35% secondary laryngectomy had to
be performed. Peretti et al. [84] published results of
11 patients with T3 glottic carcinomas treated with laser
microsurgery. The local control rate was 71.6% and the
larynx preservation rate 72.7%.
Hinni et al. [85] reported the results of 117 patients with
advancedlaryngealcarcinomasundergoinglasermicrosur-
gery. Seventy-five (64%) patients had supraglottic and
42 (36%) glottic carcinomas. Oncologic results were not
stratified for the two laryngeal subsites. Eleven (9%) tu-
mors were classified as pT2, 73 (62%) as pT3, and
33 (28%) as pT4. Unilateral or bilateral neck dissection
was performed in 92 (79%) patients and 45 patients
(34%) underwent adjuvant radiotherapy. Postoperative
complications following surgery of the primary tumor oc-
curredin8.5%ofpatientsandtheperioperativemortality
rate was 3%. The Kaplan-Meier 5-year laryngeal preser-
vation rate was 86%. The 5-year overall survival rate was
55%andthe5-yeardisease-freesurvival58%.Atthetime
of the last follow up examination, 2 of 68 (3%) survivors
had a tracheostoma and 5 (7%) were dependent on a
feeding tube. A similar study was published by Vilaseca
etal.[86]including147patientswithT3laryngealcancer
(96supraglotticand51glotticlesions).Unilateralorbilat-
eral neck dissection was performed in 66.4% of patients
and 17% were subjected to adjuvant radiotherapy. The
Kaplan-Meier 5-year larynx preservation rate was 76.6%
for supraglottic and 58.9% for glottic tumors. In a mul-
tivariate analysis the parameter “fixation of the vocal
cord” was shown to be a negative predictor for preserva-
tion of the larynx and its function.
3.3.2 Results of Open Vertical Partial
Laryngectomy
Localcontrolratesestimateto52%–76%inpatientswith
glottic carcinomas with impaired vocal cord mobility
treatedwithopenverticalpartiallaryngectomy[41],[87].
Total laryngectomy is frequently indicated in glottic car-
cinomas with vocal cord fixation. A few selected cases
aremanagedbyhemilaryngectomy.Inthosepatientsthe
local control rates average between 73% and 83% after
partiallaryngectomy[88],[89],[90],[91].Patientstreated
with primary laryngectomy and bilateral neck dissection
with or without adjuvant radiotherapy reached local con-
trol rates of 69%–87%, 5-year overall survival rates of
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71%–78% [92], [93], [94].
3.3.3 Results of Supracricoid Partial
Laryngectomy
Another organ-preserving treatment option for glottic tu-
mors with impaired vocal cord mobility or vocal cord fix-
ation is the supracricoid partial laryngectomy with
cricohyoidoepiglottopexy (SCPL-CHEP), without [95], [96]
or with neoadjuvant chemotherapy with cisplatin and
5-fluorouracil [97], [98], [99]. As contraindications for
this procedure are generally regarded fixation of the
arytenoid cartilage, subglottic tumor extension to the
upper border of the cricoid cartilage, infiltration of the
cricoidcartilageorthyroidcartilage,extensiveinfiltration
of the preepiglottic space, and extralaryngeal tumor
spread [100].
Laccourreye et al. [99] reported in 1999 on 100 patients
withT2glotticcarcinomastreatedwithSCPL-CHEP.Vocal
cord mobility was impaired preoperatively in 54% of pa-
tients. The anterior commissure was involved in 42% of
cases,andtherewasinvolvementoftheinfraglotticregion
in 10%. Patients received three cycles of neoadjuvant
chemotherapywithcisplatinand5-fluorouracilatintervals
of15–21days.Completeremissionwasachievedin24%
ofpatientsandpartialremissionin58%.The5-yearlocal
control rate was 97.7% for T2a and 93.8% for T2b car-
cinomas. The larynx was preserved in 95% of patients.
Nine per cent of patients suffered from postoperative
aspiration pneumonia; one patient had a total laryngec-
tomy for functional failure. Using the same treatment re-
gimen for glottic carcinoma with vocal cord fixation in
20patients,Laccourreyeandhisgroupachieveda3-year
localcontrolrateof89.2%andalarynxpreservationrate
of 90% [97]. Chevalier et al. [96] reported similar results
in112patientswithglotticcarcinomawithimpairedvocal
cordmobility(n=90)orvocalcordfixation(n=22)without
the use of neoadjuvant chemotherapy. The 5-year local
controlratewas97.3%andthe5-yearlarynxpreservation
rate 95.5%.
In another study by Laccourreye’s group, Dufour et al.
[101] reported on the oncologic results of 118 patients
with “endolaryngeal” carcinomas classified as T3 who
weretreatedwithSCPL.In66(56%)patientssupraglottic
carcinomas,in43(36%)patientsglotticcarcinomas,and
in 9 (8%) transglottic carcinomas were diagnosed. One-
hundred (85%) patients received 2–6 cycles of neoad-
juvant chemotherapy with cisplatin and 5-fluorouracil.
Ninety-nine (84%) patients underwent uni- or bilateral
neck dissection and 24 (20%) patients had adjuvant ra-
diotherapy. In 106 of 118 (89.8%) cases a functional
larynxcouldbepreserved.Incourseoffollowup63(53%)
patients deceased. In 30% the cause of death was a
secondprimarytumorand27%deceasedduetointercur-
rentdiseases.Dataontherapy-relatedcomplicationsand
mortality are not reported.
3.3.4 Results of Radiotherapy
LocalcontrolratesafterprimaryradiotherapyofT2glottic
carcinoma with impaired vocal cord mobility average
between 60% and 76%, and the rate of larynx preserva-
tionbetween70%–80%[102],[103],[104],[105],[106],
[107], [108]. Fein et al. [105] achieved a 5-year local
control rate of 87% for T2 glottic carcinomas with normal
vocal cord mobility. This rate declined to 76% when vocal
cord mobility was impaired. 5-year local control rates of
30%–68% are reported for primary radiotherapy of
T3 glottic carcinomas, with definitive local control rates
of 80%–86%. The 5-year overall survival rate is
51%–59%. The 5-year larynx preservation rate is
60%–76% [102], [109], [110], [111].
Two studies were highly influential on the treatment of
advanced laryngeal carcinomas, particularly in the USA.
One of these studies was conducted by the Department
ofVeteransAffairsLaryngealCancerStudyGroupin1991
[112]. Two groups of selected patients with laryngeal
carcinomas were compared. One group was treated with
induction chemotherapy followed by radiotherapy; the
otheroneunderwentprimarylaryngectomyandadjuvant
radiotherapy. Comparing the survival rates of these
groups only minimal differences could be found.
AsecondstudypublishedbytheRadiationTherapyOnco-
logy Group (RTOG) 91-11 study in 2003 [113] came to
the conclusion that simultaneous chemoradiotherapy is
superiortosequentialchemoradiotherapyorradiotherapy
alone. Included in this study were T2, T3, and “low
volume” T4 carcinomas. The authors conclude that sim-
ultaneouschemoradiotherapycanberegardedstandard
treatment for patients demanding an organ-preserving
approach under the prerequisite, that the tumor treated
corresponds to the inclusion criteria of the study. In the
authors’ opinion, primary non-surgical treatment is feas-
ible for the majority of patients and total laryngectomy
should strictly be reserved to “salvage surgery”.
Critical analysis of the data could show that both studies
had included predominately patients with supraglottic
carcinomas, 61% in the VA-study and 68% in the RTOG
91-11-study. In addition, 48% patients in the VA-study
and 42% of in the RTOG 91-11-study had mobile vocal
cords.Thesepatientscouldhavejustaswellbeentreated
with a partial laryngectomy. Since both studies included
patients with intact vocal cord mobility a conclusion on
treatment results of primary chemotherapy in patients
with vocal cord fixation can not be drawn. A French study
by the GETTEC (Groupement d’Etudes des Tumeurs de
la Tête et du Cou), comparing induction chemotherapy
followed by radiotherapy with surgery and postoperative
radiationinpatientswithlaryngealcarcinomaswithvocal
cord fixation had to be terminated due to significantly
poorer results of chemoradiotherapy [114]. In another
study on the feasibility of larynx preservation, 104 larynx
cancerpatientsweretreatedwithinductionchemotherapy
followed by radiotherapy which resulted in a 31% 5-year
laryngeal preservation rate [115].
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and RTOG-study, respectively, had a Karnofsky index of
>90 only 70% of patients could complete the entire
chemoradiation protocol due to toxicity. Eighty-two per
cent of patients suffered from grade 3 and 4 toxicity, 5%
died due to therapy-related complications. In summary,
therapy-related mortality is significantly higher when or-
gan-preservation protocols are used than after primary
surgical treatment.
Causedbytheresultsofthosetwostudies,manyoncology
centers especially in the United States treated their pa-
tientswithadvancedlaryngealcarcinomaswithsimultan-
eous chemoradiotherapy in the hope of organ preserva-
tion. In 2006, Hoffmann et al. [116] stated for the first
time, that survival rates for carcinomas of all locations
had increased during the last two decades except for
cancerofthelarynx.Inparticularremarkableistheobser-
vation that survival rates decreased in patients with ad-
vanced laryngeal carcinomas, early supraglottic carcino-
mas,andsupraglotticcarcinomasclassifiedasT3N0M0.
Moreover among all patients with laryngeal carcinomas,
classified T3N0M0, regardless of the tumor location, the
bestsurvivalrate(65.2%)wasdocumentedafterprimary
surgery and adjuvant radiotherapy. In 2007, Chen and
Halpern [117] analyzed data collected by the National
Hospital-BasedCancerRegistry.Thedatabasecomprises
7,019 cases. They found that the risk of death was signi-
ficantly higher in T3 larynx cancer patients after
chemoradiation than after laryngectomy alone.
Recently, a more critical assessment developed and has
challenged the concept of larynx preservation by various
chemoradiation protocols, due to a significant number
oflatecomplications,functionalimpairmentsandlocore-
gional recurrences [118], [119].
3.4 Conclusion
The role of laser microsurgery in the treatment of laryn-
geal carcinomas with vocal cord impairment or fixation
cannot yet be definitively assessed on the basis of the
currentliterature.Nevertheless,resultspublishedtodate
indicate that approximately 70% of patients with pT2b
andpT3carcinomasremainfreeoflocaltumorrecurrence
after primary laser surgery, with minimal morbidity and
a functional larynx. Results of laser microsurgery for
T4 glottic carcinomas cannot be considered because
adequate data are not yet available.
Comparing the results of vertical partial laryngectomy to
lasermicrosurgeryisdifficultbecausepatientsareselec-
ted for partial laryngectomy on an individual basis and
total laryngectomy may already be indicated in patients
with T2b and T3 tumors. The local control rates achieved
with supracricoid partial laryngectomy are excellent. It
shouldbenoted,however,thatthepatientswereselected
according to the criteria stated. Due to the surgical pro-
cedure itself (and due to prior induction chemotherapy
applied in many cases), morbidity is high. This is the
reason, why supracricoid partial laryngectomy is not an
option for all patients.
The results of the studies, investigating the feasibility of
larynxpreservationwithinductionchemotherapyfollowed
by radiotherapy or with simultaneous chemoradiation in
selected patients, show that this concept cannot be re-
garded as standard treatment presently. The fact that a
decrease in survival rates parallels the increase in pop-
ularity of organ-preserving chemoradiation seems worri-
some.
4. Supraglottic Carcinomas
4.1 Definition
Early supraglottic carcinomas are defined as tumors not
infiltrating the preepiglottic fat, not immobilizing a vocal
cord, and not metastasizing to lymph nodes of the neck.
Supraglottic carcinomas with vocal cord fixation and/or
invasion of the preepiglottic fat, the postcricoid region
and/or with erosion of the inner cortex of the thyroid
cartilage are classified as T3 tumors. Surgical treatment
options for supraglottic carcinomas comprise open
supraglottic laryngectomy, transoral laser microsurgery,
and supracricoid partial laryngectomy with
cricohyoidopexy.
4.2 Open Supraglottic Laryngectomy
Supraglottic laryngectomy was first described by JM
Alonso in 1947 [120]. The procedure consists of a resec-
tion of the entire supraglottis such as the epiglottis, the
preepiglottic fat, and the ventricular folds together with
the supraglottic part of the thyroid cartilage. Contraindic-
ations are tumors involving the glottis, the floor of the
ventricles, infiltrating the thyroid cartilage, the base of
the tongue extensively, and impair vocal cord mobility.
With regard to these requirements open supraglottic
laryngectomycanbeindicatedforT1,T2,andforselected
T3 carcinomas.
The procedure starts with a U-shaped skin incision. The
skin flap is elevated in the subplatysmal plane, followed
by a tracheostomy. After a bilateral (selective) neck dis-
section the infrahyoid muscles are dissected from the
hyoid bone and rotated caudally. An incision is made
throughtheexternalperichondriumofthethyroidcartilage
and the perichondrium is carefully dissected from the
cartilage down to the vocal cord plane and the superior
cornu of the thyroid cartilage is exposed. The thyroid
cartilage is then transected horizontally. The pharynx is
opened in the vallecula and the larynx exposed. Both
aryepiglotticfoldsaretransectedandtheincisionfollows
theflooroftheventriclesabovetheanteriorcommissure.
The hyoid bone or if resected the base of the tongue is
sutured with the laryngeal remnant for closure. Then the
perichondrial flap is sutured to the hyoid bone and the
infrahyoid muscles are sutured superiorly. In advanced
tumors the resection can be extended to the base of the
tongue or one arytenoid cartilage.
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cricohyoidopexie (SCPL-CHP) was first described by
Labayle[121].Theindicationforthisprocedurecomprises
supraglottic tumors with limited infiltration of the preepi-
glottic fat, limited erosion of the thyroid cartilage and tu-
mors with fixation of one vocal cord but without fixation
of the arytenoid cartilage. This operation was used for
surgical treatment of T1, T2 and selected T3 and T4
supraglottic tumors.
After elevating the skin flap, tracheostomy, and neck
dissection the strap muscles are divided in the midline.
The thyrohyoid muscle and the sternohyoid muscle are
dissected from the hyoid bone. The thyroid cartilage is
skeletonized and the constrictor pharyngis muscle re-
leased from the cartilage. The larynx is opened in the
valleculaandtheincisionmadeanteriortothearytenoids
cartilage and the superior border of the cricoid cartilage
isdissected.Bothvocalfolds,ventricularfolds,epiglottis,
andpreepiglotticfatareremovedtogetherwiththethyroid
cartilage.Closureisperformedbyimpactionofthecricoid
cartilage to the hyoid bone. The strap muscles are then
sutured and the skin flap is closed.
VaughanfromBoston[122]wasthefirstsurgeondescrib-
ing a supraglottic partial laryngectomy carried out
transorally with a carbon dioxide laser. Since 1979
Steiner used the carbon dioxide laser for transoral endo-
scopicsurgeryofselectedsupraglotticcarcinomas[123],
[124].In1983,Davisetal.[125]reportedonafirstseries
of 20 patients with benign bulky lesions obstructing the
airway or small suprahyoid carcinomas of the epiglottis
that were treated with laser epiglottectomy. Later Davis
et al. [126] and Zeitels et al. [127] published the results
oflasermicrosurgeryinselectedpatientswithsupraglottic
carcinomas. T1 and T2 as well as selected T3 and T4
carcinomas were resected with this method.
The rare small carcinomas of the suprahyoid epiglottis
or ventricular fold can usually be easily exposed and ex-
cised en bloc. Carcinomas of the infrahyoid epiglottis are
exposed with a bivalved laryngoscope and are best re-
moved piecemeal by making an incision in the vallecula
glossoepiglotticaandsplittingtheepiglottisinthemidline,
resecting the preepiglottic fat while preserving the vocal
folds and arytenoid cartilages (Figure 5, Figure 6). Tumor
that has spread along the inner surface of the thyroid
cartilageandinfiltratesthemuscletissueintheparaglot-
tic space on the glottic level can be removed along with
partsofthevocalismuscle.Withadvancedtumors,parts
of the base of the tongue, piriform sinus or one arytenoid
cartilage can be included in the resection [3] (Figure 7).
The extent of laser resection is limited by the patient’s
abilitytoregainadequateswallowingfunction.Toprevent
postoperative bleeding the superior laryngeal artery
should be identified and liger clipped (Figure 8).
Tracheostomyisgenerallyunnecessaryduetoverylimited
postoperative edema, even after extensive supraglottic
laser resections. A tracheotomy should be considered in
elderly patients with significantly impaired pulmonary
function, in patients with a bleeding diathesis (e.g., anti-
coagulantmedication,hemodialysis),orifheavybleeding
occurred during surgery.
Figure5:Anatomicspecimen,non-fixed.Thedottedlinesshow
the resection in case of a supraglottic carcinoma.
Figure 6: Right adult hemilarynx. Specimen of the scientific
collection of the Inst. of Anatomy of CAU Kiel. Photograph: B.
Tillmann. The dotted lines show the resection in a case of a
supraglottic carcinoma with complete resection of the
epiglottis, the preepiglottic fat and the false cord.
Figure7:Anatomicspecimen,non-fixed.Thedottedlinesshow
the resection in a case of an advanced supraglottic carcinoma
with the resection extended to the aryepiglottic fold and the
arytenoid cartilage.
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4.2.1 Special Aspects of Histopathologic
Examination
As a rule most supraglottic carcinomas are resected in
multiple blocks. Marking the specimens precisely is es-
sential for an adequate orientation for histopathologic
examination[5].Nomatterwhichsurgicalmethods(open
surgeryorlasermicrosurgery)arebeingused,tumorfree
resection margins must be achieved to prevent tumor
recurrence. Prades et al. [128] reported in a series of
110patientsin23%ofcasesmicroscopicpositiveresec-
tion margins after open supraglottic laryngectomy. The
risk for a local tumor recurrence was 4 times higher in
these patients despite adjuvant radiotherapy. Iro et al.
[129] pointed out that favorable oncologic results in
transoral laser supraglottic resections could only be
achieved with tumor free resection margins (R0 resec-
tion). In case tumor free resection margins can not be
achievedtheyrecommendtransorallaserre-resectionor
open supraglottic laryngectomy, alternatively total laryn-
gectomy. Adjuvant radiotherapy did not prove efficacy in
theR1andR2situationandwasthereforenotrecommen-
ded.
Blanch et al. [130] analyzed the prognostic implications
of positive resection margins in 357 patients with laser
micro surgically resected tumors of the larynx and
pharynx.Theycouldshowthatpositiveresectionmargins
were associated with higher rates of local recurrences,
distant metastases, loss of organ, and poorer survival.
Theseresultsacknowledgetheimportanceofre-resection
if tumor-free surgical margins are not achieved after the
first surgery. Jäckel et al. [131] examined the prognostic
relevance of positive margins in 1,467 patients treated
laser microsurgically because of tumors in various sites
of the upper aerodigestive tract. The authors could show
that the prognosis did not worsen when tumor-free sur-
gical margins were achieved by re-resection. The risk for
a local recurrence was higher in patients with residual
tumorinthere-resectionspecimen.Inthosecasesanoth-
er re-resection was advocated.
4.2.2ClassificationofEndoscopicSupraglottic
Laryngectomy
In 2009, Remacle et al [132] published on behalf of the
European Laryngological Society a proposal for the clas-
sificationofendoscopicsupraglotticlaryngectomy.Accord-
ing to the extent of resection, supraglottic partial resec-
tions are classified in seven types. If this complex classi-
fication system will be incorporated into clinical practice
is still undecided.
4.3 Complications
Thecomplicationrateisamajorconcernwhenevaluating
atherapeuticprocedure.Themostcommoncomplications
after open supraglottic laryngectomy are postoperative
endolaryngeal hemorrhage, pharyngocutaneous fistula,
andsupraglotticstenosis.Theincidenceofpostoperative
hemorrhageisaboutequalforopensupraglotticlaryngec-
tomy, SCPL-CHP, and laser microsurgery with an average
between3%–14%indifferentstudies[133],[134],[135],
[136],[137].However,everypostoperativebleedingafter
endoscopic surgery in a non-tracheotomized patient is a
serious and potentially life-threatening complication due
to the risk of aspiration of blood [138]. Nevertheless,
bleedingfromthebaseoftongueorthelaryngealremnant
with fatal outcome has been described after open
supraglotticlaryngectomy[139],[140].Anupto18%rate
of surgical complications has been reported after
SCPL-CHP [141], [142].
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SCPL increases with age and pre-existing pulmonary dis-
ease. This explains why patients older than 60 years of
age normally do not qualify for CHP [143].
Laryngeal stenosis occurs less often after endoscopic
supraglottic resection than after open supraglottic laryn-
gectomyorSCPL-CHP.Theincidenceisreported0%–10%
afterlasersupraglotticresectionand5%–15%afteropen
supraglottic laryngectomy [136], [137], [144].
Themostprevalentcomplicationsafterprimaryradiother-
apy are chondronecrosis and the airway obstructing
laryngeal edema. The incidence of severe complications
amounts to 2%–7% [145], [146], [147]. In 1.5% to 2%
of patients secondary laryngectomy is required after irra-
diationofasupraglotticcarcinomaduetochondronecros-
is or persistent laryngeal edema. Another 0.6%–2.5% of
patients need a permanent tracheostoma [145], [146],
[147].
Adjuvant radiotherapy is not indicated in patients with
completeremovaloftheprimarytumorandhistopatholo-
gically tumor-free cervical lymph nodes. Adjuvant radio-
therapy is indicated in cases where microscopic residual
tumorisassumedtobepresentattheprimarytumorsite
(R1 resection), in patients with more than one tumor
positive lymph node in the neck and in patients with
lymph node metastases with extracapsular spread.
Whether postoperative radiotherapy after supraglottic
laryngectomyhasanadverseeffectonlaryngealfunction
iscontroversial.Steiningeretal.[148]foundthatpatients
receiving postoperative irradiation were more likely to
need lifelong PEG tube feeding and were also more likely
to have airway obstruction due to edema. Other studies
foundnoincreaseincomplicationratesfollowingadjuvant
radiotherapy [149], [150]. It is reasonable to assume,
however,thatthecomplicationrateincreaseswhendoses
higher than 50 Gy are applied to the larynx [150], [151].
4.4 Oncologic Results
4.4.1 Results of Open Supraglottic
Laryngectomy
The oncologic results of open supraglottic laryngectomy
in early supraglottic carcinomas are excellent. The local
control rate is between 90%-100% for T1 tumors and
80%-97%forT2tumors[152],[153],[154],[155],[156],
[157], [158], [159], [160], [161], [162].
In the recent literature (since the year 2000) only a few
articles are found on open supraglottic laryngectomy.
Prades et al. [128] report on 110 patients with T1-T3
supraglotticcarcinomas.Thelocalcontrolratewas90.3%
and the 5-year overall survival rate 52%. Similar results
were published by Bron et al. [163] for 75 patients with
T1-T3 supraglottic carcinomas. In this series, the 5-year
localcontrolratewas92.5%,theorganpreservationrate
was98.5%,andthe5-yearoverallsurvivalratewas75%.
A retrospective analysis of 267 patients (187 T1/T2-car-
cinomas, 80 T3/T4-carcinomas) done by Sevilla et al.
[164] showed also comparable results. In this study the
local control rate was 92% and the larynx could be pre-
served in 82% of patients. The 5-year disease-specific
survival rate was 92% for stage I and 71% for stage II.
Fifteen per cent of patients needed a permanent
tracheostoma and 9% had to undergo secondary laryn-
gectomy due to functional reasons.
The local control rates achieved for T3 carcinomas with
classicorextendedopensupraglotticlaryngectomyrange
from 71% to 94% [157], [165], [166], [167].
4.4.2 Results of Supracricoid Partial
Laryngectomy
SCPL-CHP can be performed in carcinomas with infiltra-
tion of the ventricle or the paraglottic space (T2 or T3 tu-
mors).Schwaabetal.[142]reporton146patientsmostly
with T2 and T3 carcinomas who underwent SCPL-CHP.
The local control rate was very good, with only 4% devel-
oping local recurrence. In 19% clinically relevant aspira-
tion was noticed postoperatively and 9% had to be
laryngectomizedduetointractableaspiration.Thelarynx
couldbepreservedin85%ofpatients.The5-yearoverall
survival rate was 88%.
The local recurrence rate after SCLP-CHP is also very low
in other series, ranging from 0% to 7% [43], [168], [169],
[170]. It should be noted, however, that most of the tu-
mors treated with SCLP-CHP were T2 and T3 carcinomas
with “minimal infiltration” of the preepiglottic space, tu-
mors involving the paraglottic space or vocal cords, or
tumors classified as T4 lesions with only “minimal” infilt-
ration of the thyroid cartilage [142], [168], [169].
4.4.3 Results of Laser Microsurgery
While laser microsurgery is used increasingly in the
treatment of glottic carcinomas, only few reports have
beenpublishedontheendoscopicresectionofsupraglot-
ticcarcinomas.Steiner[25]andEckelandThumfart[171]
reported respectively on 30 and 15 patients with supra-
glotticcarcinomas.Zeitelsetal.[172]analyzedtheresults
of laser microsurgery in 42 patients with supraglottic
carcinomas in a multi-institutional study. Nineteen pa-
tients with T1 or T2 tumors treated with laser microsur-
gery alone were cured. Of 23 patients, mostly with
T2 tumors, who received both surgery and postoperative
irradiation, 4 developed local recurrences and were
salvaged by total laryngectomy. In 1997, Eckel [173] re-
ported the results of supraglottic laser resection in
46 patients with T1 and T2 tumors. Four (8.7%) patients
developed local or locoregional recurrences, 5 (10.9%)
required secondary laryngectomy due to functional reas-
ons. Iro et al. [129] reported in 1998 on transoral
supraglottic laser resections in 141 patients with the
following UICC stage distribution: stage I, 23.4%; stage
II, 25.5%; stage III, 16.3%; and stage IV, 34.8%.
In 1999, Rudert et al. [135] reviewed the results of
transoral laser microsurgery in 34 patients with
T1-T4 tumors, 12 of whom were treated with palliative
intent. None of the patients who underwent the surgery
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year overall survival rate for stages I and II disease was
88%.Ambroschetal.[134]performedlasermicrosurgery
in 48 patients with supraglottic T1 and T2 carcinomas.
The 5-year local control rate was 100% for pT1 tumors
and 89% for pT2 tumors. None of the patients required
secondarylaryngectomyfortumorrecurrenceorfunction-
al reasons. The 5-year recurrence-free survival rate in
this series was 83%, and the 5-year overall survival rate
was 76%.
Since2000aseriesofstudieshavebeenpublishedabout
therapy results of transoral supraglottic laryngectomy.
Grant et al. [174] reported on behalf of the Mayo-group
on 38 patients with supraglottic carcinomas (T1/T2
22 patients, T3/T4 16 patients). The 2-year local control
rate was 97%. In 79% of the patients a functional larynx
could be preserved. Remarkably, the majority of patients
(20 out of 38) received a tracheostomy due to various
reasons. Agrawal et al. [175] published a prospective
phase2-studyfortheSouthwestOncologyGroupinwhich
34 patients with supraglottic carcinomas were included
(T1 7 patients, T2 27 patients). According to the study
protocol, laser microsurgical supraglottic laryngectomy
followed by radiotherapy was performed in all patients.
Only one patient developed a local recurrence and had
to undergo total laryngectomy. Nine per cent of the pa-
tients suffered persistently from severe swallowing
impairment.Ithastobenotedthatacombinedtreatment
protocol for early supraglottic carcinoma is an overtreat-
ment for those tumors. As to be expected, patients
demonstrated good local control but with a substantial
numberoffunctionalfailures.Bumberetal.[176]treated
64patientswithsupraglotticcarcinomas(T129patients,
T2 35 patients) with transoral laser resections. Two pa-
tients developed a local recurrence and needed total
laryngectomy. Another patient had to undergo total
laryngectomyduetofunctionalreasons.The5-yearrecur-
rence-free survival rate was 93%.
Two recent studies compare open supraglottic laryngec-
tomywithtransorallasermicrosurgery.Bussuetal.[177]
compare 78 patients treated with open surgery with 70
patients undergoing endoscopic supraglottic laryngec-
tomy. While organ preservation rate and survival rate
showednostatisticallysignificantdifference,thefunction-
alresultsweredistinctivelybetterafterlasermicrosurgery.
Karatzanis et al. [178] describe 101 patients with
T1-T2N0 supraglottic carcinomas undergoing transoral
lasermicrosurgery(n=49),opensupraglotticlaryngectomy
(n=29), or total laryngectomy (n=23). Comparing local
control rates and disease-specific survival rates of the
three groups, no statistically significant difference was
noted.Eventhoughnotstatisticallysignificant,therewas
a trend towards better functional outcome in the
transoral laser microsurgery group. Those patients had
lesscomplicationsandfewerpermanenttracheostomies
and PEG tubes than patients after open supraglottic
laryngectomy.
There are few reports on laser surgery for supraglottic T3
carcinomas in the literature. Rudert et al. [135] report
results in 9 patients with T3 carcinomas (4 treated with
palliative intent) and 8 patients with T4 carcinomas
(5 treated with palliative intent). Two of 9 patients (22%)
with T3 tumors and 5 of 9 patients (63%) with T4 tumors
developed local recurrences. In the series of Iro et al.
[129], a local recurrence was diagnosed in 5 of 15 pa-
tients (33%) with T3 carcinomas and in 3 of 33 patients
(9%) with T4 carcinomas. While Rudert et al. [135] state
that supraglottic carcinomas with invasion of the preepi-
glottic fat are endoscopically resectable, Iro et al. [129]
adviserestraintintreatingT3tumorswithtransorallaser
surgery.
Ambrosch et al. [28] treated 50 patients with pT3 supra-
glottic laryngeal carcinomas (40 stage III, 10 stage IV)
with transoral laser microsurgery. In 41 (82%) patients,
the tumor was classified pT3 due to invasion of the
preepiglottic fat; in 9 (18%) patients vocal cord fixation
waspresentpreoperatively.In13(26%)patientsinvasion
of the paraglottic space and in 9 (18%) cases superficial
tumor spread to one or both vocal cords was diagnosed.
These patients were treated with laser microsurgery as
an alternative to extended supraglottic laryngectomy,
SCPL-CHP, or total laryngectomy. The 5-year local control
rate was 86%. Four per cent of the patients underwent
total laryngectomy due to local tumor recurrence. The
5-yearrecurrence-freesurvivalratewas71%.Allpatients
had good vocal function. One patient developed a
supraglottic stenosis after surgery followed by adjuvant
radiotherapy and required a permanent tracheostoma.
Allpatientswereonanunrestrictedoraldietafterremoval
of the feeding tube. Special swallowing training was not
required.Noneofthepatientsneededtotallaryngectomy
for functional reasons.
Motta et al. [179] achieved a local control rate of 77%
and an overall survival rate of 81% in 18 T3 supraglottic
cancer patients treated with laser microsurgery. Peretti
et al. [180] reported on a series of 80 patients treated
with laser microsurgery in which 20 patients with pT3 le-
sions showing “limited infiltration” of the preepiglottic
fat.In88.2%ofpatientslarynxpreservationwasachieved,
the 5-year disease-free survival was 59.6%.
Based on the current literature it can be concluded that
laser microsurgery is an alternative to open supraglottic
laryngectomy.Althoughlocalrecurrenceratesareslightly
higherwithlasermicrosurgery,survivalratesarecompar-
able.Lasermicrosurgery,opensupraglotticlaryngectomy,
and SCLP-CHP show similar results with regard to larynx
preservation. This is due to higher secondary laryngec-
tomy rates, reported in some series above all after
SCPL-CHP, due to intractable aspiration.
4.4.4 Results of Radiotherapy
With primary radiotherapy supraglottic T1 carcinomas
canbelocallycontrolledin75%-100%andT2carcinomas
in 62%–83% of cases [181], [182], [183], [184], [185],
[186], [187]. While Inoue et al. [185] obtained signific-
antly better local control rates for tumors of the epilarynx
thanfortumorsoftheinfrahyoidepiglottis,otherauthors
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subsites of the supraglottis [184], [188]. A significant
predictor for local control, however, is the tumor volume
determined by computed tomography [189].
Published data show that patients whose tumors could
have been treated with voice preserving partial laryngec-
tomy will usually require total laryngectomy in case of
recurrence after primary radiation therapy. Johansen et
al. [190] treated 117 patients with early supraglottic
carcinomas with primary radiotherapy; 31% of patients
required a total laryngectomy because of tumor recur-
rence. In the cohorts of Inoue et al. [185], Mendenhall
et al. [186], and Johansen et al. [191] 17%, 14%, and
27% of patients, respectively, had to undergo salvage
laryngectomy.
In supraglottic T3 carcinomas local control rates of
50%–76% can be achieved with primary radiotherapy
[145], [146], [147], [181], [191]. Hinerman et al. [147]
were able to preserve the larynx in 68% of their patients
treated with radiotherapy for supraglottic T3 carcinomas
and Nakfoor et al. [145] in 72%. In the series done by
Johansen et al. [191], 36% (31 out of 87) of supraglottic
T3 carcinoma patients treated with primary radiotherapy
had to undergo salvage laryngectomy. The following sur-
vival rates have been reported: the corrected 5-year sur-
vival rate was 53% in the series of Sykes et al. [146], the
5-yearrecurrence-freesurvivalratewas76%intheseries
of Nakfoor et al. [145], and the 5-year disease-specific
survival rate for stage III carcinomas was 81% in the
series of Hinerman et al. [147].
The results of studies investigating the efficacy of
chemoradiation protocols for larynx preservation [112],
[113] have been discussed in the “glottic carcinoma”
section.
4.5 Functional Results
All authors who have reported on the transoral laser re-
sectionofsupraglotticcarcinomasagreethatswallowing
rehabilitation proceeds more quickly and has better out-
comes than open supraglottic laryngectomy. The rate of
secondary laryngectomy for persistent aspiration after
open supraglottic laryngectomy is in the range of
3.5%–12.5% [128], [149], [152], [164]. The incidence
of postoperative aspiration and the time needed for
swallowing rehabilitation varies with age, general health
condition, and with the extent of resection of the base of
tongue and arytenoid cartilage [133], [192], [193]. Due
to considerable morbidity and postoperative functional
impairment, open supraglottic laryngectomy often does
not qualify as a treatment option, particularly in elderly
patients with pre-existing pulmonary disease.
Onthewhole,thefunctionalresultsoflasermicrosurgery
for supraglottic T1-T3 carcinomas are very favorable.
Patients need nasogastric tube feeding normally for a
few postoperative days. Aspiration is minimal and occurs
in the early postoperative period only and there is a re-
ducedneedforsecondarytracheostomyandlaryngectomy
due to aspiration problems [28], [129], [134], [137],
[178], [194], [195].
Mechanisms contributing significantly to the recovery of
swallowing function after supraglottic, either open or
endoscopic laryngectomy are: the oropharyngeal transit
time of the bolus, closure of the airway at the laryngeal
entrance,thepositionofthelaryngealremnantinrelation
to the base of the tongue, and the movement of the base
ofthetonguetowardtheposteriorpharyngealwall[193],
[196], [197]. Patients who regain these functions post-
operativelymeettheprerequisitesforanormalswallowing
function.
We attribute the early and consistently successful swal-
lowing rehabilitation in the patients treated by us to a
variety of factors. The avoidance of tracheotomy, the in-
tegrityofthebaseofthetongueandpharyngealmuscles
and the preservation of the hyoid bone with the supra-
and infrahyoid muscles, enable the larynx to move nor-
mally during deglutition. At least one mobile arytenoid
cartilage was preserved in all operations, to enable
functional closure of the larynx. We also believe that
preserving the extralaryngeal portions of the superior
laryngeal nerves is an important factor in sensory rein-
nervation.
In most patients undergoing a supracricoid partial laryn-
gectomy,thefeedingtubecanberemovedwithinamonth
after surgery. But the patients will require 6–12 months
to return to their normal eating habits [43], [45], [170],
[198]. Approximately one third of patients will have to
accept permanent limitations [45], [198]. SCPL also
causes an inevitable change in voice quality, which can
adversely affect the quality of live, especially in female
patients [45].
4.6 Conclusion
As for early glottic carcinomas, there are little data found
on open surgery for early supraglottic carcinomas in re-
cent literature. The results of laser microsurgery in pa-
tients with T1-T3 supraglottic cancer are comparable to
those of open supraglottic laryngectomy with regard to
local control and survival rates. Transoral microsurgery
makes it possible to preserve functionally important
structures, thereby reducing alterations in the mobility of
the laryngeal remnant and pharynx thus facilitating
earlier and better swallowing. With the low postoperative
morbidity of laser microsurgery, curative surgical treat-
mentcanbeofferedtopatientswhowouldnothavebeen
consideredcandidatesforopensupraglotticlaryngectomy.
Theresultsoftransoralmicrosurgeryandopensupraglot-
tic laryngectomy are somewhat better than the results
published for primary radiotherapy with regard to local
control and survival, and they are superior with respect
to organ preservation.
On the basis of current data, the concept of induction
chemotherapy followed by radiotherapy or simultaneous
chemoradiationwiththeaimoflarynxpreservationcannot
be regarded as standard treatment at the present time.
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5.1 Preliminary Remarks
Hypopharyngeal carcinoma has the poorest prognosis
among all carcinomas of the upper aerodigestive tract.
This is due mainly to a high rate of local tumor recur-
rences, a high prevalence of cervical lymph node meta-
stasis at the time of diagnosis, a high rate of syn- and
metachronous distant metastases and second primary
tumors,andahighrateofalcoholandtobaccoconsump-
tion and consumption-related diseases.
The National Cancer Data Base Report of the year 1997,
tothisdaythereportwiththelargestdataoncarcinomas
of the hypopharynx, indicates a 5-year disease-specific
survival rate of 31.4% in 3,906 cases of hypopharyngeal
carcinoma and a 33.6% survival rate in 822 cases of
carcinomasofthepiriformsinus[199],[200].Regardless
of treatment, the 5-year disease-specific survival rate in
the cohort of 1,295 patients treated between 1980 and
1985was63%forstageI,58%forstageII,42%forstage
III, and 22% for stage IV disease. Further analysis of the
data showed that patients with early-stage disease
treated with radiotherapy alone had lower survival rates
than patients who received primary surgical treatment,
withorwithoutadjuvantradiotherapy.Inadvancedstage
disease,cancerstreatedwithradiotherapyalonehadthe
poorest survival rates. In addition, the data clarified that
44% of hypopharynx cancer patients were treated with a
combined treatment consisting of surgery and radiother-
apy. With regard to surgical procedures, total laryngo-
pharyngectomy was performed in 57.5% of cases and
partial laryngopharyngectomy or other partial resections
in 25.3% of cases. Only 4% of patients underwent laser
resection. Severe treatment-related complications oc-
curred in 6–34% of cases, and fatal complications were
observed in 2.4%–14% [199].
Recent literature shows that the advances in imaging
technology, radiotherapy, chemotherapy, surgery, and
multimodalitytreatmentprotocolshavenotledtoareduc-
tion in mortality. Regarding different therapy concepts
for stage I and II hypopharyngeal carcinomas, the 5-year
survival rate averages between 52% and 77% for radio-
therapy (with or without concomitant chemotherapy)
[201], [202], [203], [204], between 56% and 77% for
supraglottic or supracricoid hemilaryngopharyngectomy
(withorwithoutinductionchemotherapy,neckdissection
orpostoperativeradiotherapy)[205],[206],[207],[208],
and between 70% and 73% for transoral laser microsur-
gery (with or without neck dissection or postoperative
radiotherapy) [209], [210], [211]. The 5-year survival
rates for stage III and IV hypopharyngeal carcinomas are
19%–37% for radiotherapy (with or without concomitant
chemotherapy)[212],[213],[214],[215],and47%–59%
for transoral laser microsurgery (with or without neck
dissection or postoperative radiotherapy) [209], [210].
Induction chemotherapy followed by radiotherapy
achieved a 5-year survival rate of 38% in stage III and IV
hypopharyngeal carcinomas [216].
Since survival cannot be improved in patients with hypo-
pharyngeal cancer, the focus should be on improving the
quality of life with organ-preserving therapy concepts in
those patients with an unfavorable prognosis.
5.2 Partial Laryngopharyngectomy
Theprincipleofsupracricoidhemilaryngopharyngectomy
(SCHLP) is to resect the tumor together with the piriform
sinus, and the ipsilateral hemilarynx above the cricoid
cartilage. After ipsilateral neck dissection is performed,
theipsilateralthyroidcartilageandhalfofthehyoidbone
is resected. The infrahyoid muscles are dissected and
rotated caudally and the larynx is opened by incision in
thevalleculaglossoepiglottica.Epiglottisandpreepiglottic
fat are then dissected in the vertical plane. The upper
rim of the cricoid cartilage defines the caudal resection
margin. After removal of the vocal fold and the ventricle,
theposteriorresectionlineisdefinedunderdirectvision.
Following mobilization of the pharynx from the deep cer-
vical fascia, the defect is closed by suturing the pharynx
to infrahyoid muscles, laryngeal remnant and vallecula.
The supraglottic hemilaryngopharyngectomy is a modifi-
cation of the supracricoid hemilaryngopharyngectomy
with preservation of both vocal folds.
Figure9:Anatomicspecimen,non-fixed.Thedottedlinesshow
the resection in a case of a carcinoma of the piriform sinus.
Optimum exposure of the larynx and piriform sinus is es-
sential for an adequate tumor resection with transoral
laser microsurgical partial laryngopharyngectomy. The
tumor is exposed with a bivalved laryngoscope and is re-
sected step by step in the cranial-to-caudal direction
(Figure 9). The position of the laryngoscope is adjusted
several times as the resection proceeds in order to keep
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the visual field of the microscope. Carcinomas of the
piriformsinusareresectedblocwisetoassesstheextent
of tumor infiltration to the depth. Aided by frozen section
analysisofresectionmargins,preservationofamaximum
amount of normal, healthy tissue is possible. Piriform si-
nustumorsareresectedwithasafetymargintothetumor
of approximately 5–10 mm. If necessary, the resection
can be extended to the oropharynx or the neighboring
cervical soft tissue [3].
5.3 Oncologic Results
5.3.1 Results of Open Partial
Laryngopharyngectomy
Oguraetal.[217]werethefirsttoreportonpiriformsinus
carcinomastreatedwithorgan-preservingpartiallaryngo-
pharyngectomy. They achieved a 3-year survival rate of
53% in highly selected patients with early piriform sinus
carcinoma (mobile vocal cords, no tumor involvement of
the apex of the piriform sinus, postcricoid region, or
thyroid cartilage). However, 34% of patients required a
secondary total laryngectomy due to local tumor recur-
rence [218]. Ogura’s indications were subsequently ad-
opted by several other laryngologists [219], [220], [221].
Henri Laccourreye et al. [222] reported in 1987 on 240
patientswhounderwentsupracricoidhemilaryngopharyn-
gectomy for early piriform sinus carcinomas. Local recur-
rences developed in 5.2% of cases. Eight per cent of pa-
tients required a tracheostoma and 15% suffered from
dysphagia.
More recently, Chevalier et al. [205] published results of
31 patients with T1 and T2 piriform sinus carcinomas
treated over a period of 15 years. Treatment consisted
of supraglottic hemilaryngopharyngectomy with radical
neck dissection and postoperative radiotherapy. While
very good local control was achieved with this concept
(local recurrences were observed in only 2% of patients),
the survival rates were low, especially in patients with T2
tumors, due to a high incidence of recurrent metastases
in the neck and distant metastases. All patients required
temporarytracheostomyandtemporarynasogastrictube
feeding.
Makeieffetal.[206]reportedon87patientswithT1and
T2piriformsinuscarcinomaswhounderwentsupraglottic
hemilaryngopharyngectomy, neck dissection and post-
operativeradiotherapyintheyears1981–1998.In19.5%
of patients local tumor recurrences developed. Due to a
large number of recurrent metastases in the neck and
second primary carcinomas (amongst others 6.9% in the
contralateral piriform sinus), the 5-year survival rate was
as low as 60.3%. All patients required a temporary
tracheostomy for a median time period of 16 days and
2 patients required permanent PEG tube feeding.
Foucheretal.[223]reportedon45patientswithT1-T2N0
hypopharynx carcinomas treated with partial
pharyngolaryngectomyandelectiveneckdissectionalone.
The 5-year locoregional control rate with this treatment
regimen was 82%.
Anotherorgan-preservingtreatmentoptioninhypopharyn-
geal cancer is neoadjuvant chemotherapy followed by
supracricoidhemilaryngopharyngectomyandpostoperat-
ive radiotherapy. Ollivier Laccourreye and his group used
thisregimentotreat118patientswithT1andT2carcino-
mas and 29 patients with T3 and T4a carcinomas of the
piriform sinus between 1982 and 2000 [224]. Induction
chemotherapywithcisplatinand5-fluoruracil(2–6cycles)
received 97.4% of patients. Complete remission was
clinically achieved in 21.7% and histopathologically
proven in 16.8% of patients. Postoperative radiotherapy
was given to 49.8% of patients. Only 8.2% of patient de-
veloped local tumor recurrence. The larynx preservation
rate was 91.2% and the 5-year survival rate was 54.9%.
The functional results were described in a consecutive
publication [208]. The postoperative mortality rate was
3.7%andsurgicalcomplications,directlyrelatedtoSCHLP
occurredin9.6%ofcases.Patientsreceivedanasogastric
feeding tube for a median time period of 22 days. A per-
manent PEG feeding tube due to aspiration was needed
in 0.7% of patients, 1.5% had to undergo completion
laryngectomy and 0.7% died because of aspiration.
5.3.2 Results of Laser Microsurgery
The first results of 36 patients with hypopharyngeal can-
cer treated with laser microsurgery were published by
Steiner and Herbst in 1987 [225]. Another report on
42patientstreatedattheDepartmentofOtorhinolaryngo-
logy at the University of Erlangen was published shortly
after [226]. Between 1988 and 2001 a series of articles
reported on results of transoral laser microsurgery in hy-
popharyngeal carcinomas [227], [228], [229].
Steineretal.[209]performedprimarylasermicrosurgery
in curative intent in 129 previously untreated patients
withsquamouscellcarcinomaofthepiriformsinusinthe
years1981–1996.Theprimarytumorswerecategorized
accordingtotheUICC/AJCCclassificationof1992aspT1
in 24 patients, pT2 in 74, pT3 in 17, and pT4 in 14 pa-
tients. Cervical lymph node metastases were present in
88 patients (68%) at the time of diagnosis. The tumors
were distributed by stages as follows: stage I in 10 (8%)
patients, stage II in 23 (18%), stage III in 26 (20%), and
stageIVin70(54%).Unilateralorbilateralpredominantly
selectiveneckdissectionwasperformedin110patients.
Six (18%) patients with stage I and II and 69 (72%) with
stage III and IV carcinomas were treated with adjuvant
radiotherapy.
Local and locoregional recurrences developed in a total
of 17 (13%) patients (stage I and II: 3/33, 9%; stage III
and IV: 14/96, 15%). The Kaplan-Meier 5-year local con-
trol rate was 82% for stage I and II and 69% for stage III
and IV. Eighteen (14%) patients developed late or recur-
rentmetastasesintheneckand8patients(6%)suffered
metachronousdistantmetastaseswithlocoregionaltumor
control. A metachronous second primary tumor was dia-
gnosed in 24 (19%) patients. The Kaplan-Meier 5-year
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for stage III and IV. The 5-year recurrence free survival
rate was 95% for stage I and II and 69% for stage III and
IV. Five (4%) patients had postoperative endolaryngeal
bleeding,whichwascontrolledendoscopicallyinallcases.
ThreepatientsrequiredPEGtubefeeding,oneforahypo-
pharyngealstenosisandtwoduetoaspiration.Allpatients
regained normal swallowing function.
Inafollowuppublication,Steinerandhisgrouppublished
in 2008 the results of 172 previously untreated patients
with squamous cell carcinoma of the piriform sinus
treatedwithprimarylasermicrosurgeryincurativeintent
intheyears1986–2003[210].Stagingwasdoneaccord-
ing to the UICC/AJCC 2002 classification. Twenty-one
patients had pT1 tumors, 48 pT2, 75 pT3, and 28 pT4
tumors.Thetumorsweredistributedbystagesasfollows:
stage I in 7 (4%) patients, stage II in 19 (11%), stage III
in52(30%),andstageIVain94(55%)patients.Unilateral
or bilateral predominantly selective neck dissection was
performed in 93% of patients. Fifty-two per cent of pa-
tients were treated with adjuvant radiotherapy.
The Kaplan-Meier 5-year local control rate was 84% for
pT1lesions,70%forpT2,75%forpT3,and57%forpT4a
lesions.The5-yearrecurrencefreesurvivalratewas73%
for stage I and II, 59% for stage III, and 47% for stage IVa.
Permanent PEG tube feeding was required in 3.5% of
patients and one patient had to undergo total laryngec-
tomy due to functional impairment. In 3.5% of cases a
tracheostomy was performed.
Rudert [230] reported the results of 29 patients with
hypopharyngeal carcinomas who were treated with laser
microsurgery at the University of Kiel between 1991 and
1995. Twenty-seven patients had T1 or T2 tumors. Eight
(28%) patients developed local recurrences. The overall
5-year survival rate was 58% and the disease-specific
survival rate was also 58%. In this study like in others,
analysisshowedthatthesurvivalratesdependedstrongly
on cervical lymph node involvement. The 5-year survival
rate was 74% for patients with N0 neck but only 34% for
patients with cervical lymph node metastases. Accord-
ingly, the survival rate was 78% for patients with stage I
or II disease versus 35% for patients with stage III or IV
disease. None of the patients required a tracheostomy
together with the primary tumor surgery and all patients
had normal postoperative swallowing function.
Vilaseca et al. [231] report on a cohort of 28 patients
treatedwithtransorallasermicrosurgery,neckdissection
andpostoperativeradiotherapy.Twopatientshadprimary
tumors classified as pT1, 16 as pT2, 9 as pT3, and 1 as
pT4. The tumors were distributed by stages as follows:
stage II in 21%, stage III in 29%, and stage IV in 50% of
patients. The local control rate was 78%. The laryngeal
function could not be maintained in 3 patients.
Karatzanisetal[211]analyzedretrospectivelythecourse
ofdiseasein119patientswithT1andT2hypopharyngeal
carcinomas who were treated with transoral laser mi-
crosurgery,neckdissection,andwithorwithoutadjuvant
radiotherapy at the University of Erlangen between 1979
and 2004. The 5-year local control rate was 90% for 45
pT1and84%for74pT2carcinomas.The5-yeardisease-
specific survival was 78% for pT1N0/N+ and 70% for
pT2N0/N+ cases. Permanent tracheostomy or PEG
feeding was required in a total of 5% of patients.
5.3.3 Results of Radiotherapy
Primaryradiotherapyoftheprimarytumorandbothsides
oftheneckachievedgoodlocalcontrolratesanddisease-
specific survival rates, particularly in T1 and T2 carcino-
masoftheupperpiriformsinus.However,thelocalcontrol
rate declines when the tumor volume exceedes 6.5 ml.
In addition, an increased risk for a functionless larynx
was seen with increasing tumor volume, even when local
tumor control was achieved [232]. Furthermore, it is
known, that operations for tumor recurrences after
primary radiotherapy are associated with complications
in a high percentage of cases. About 30%–35% of pa-
tients after secondary laryngectomy developed pharyn-
gocutaneous fistulas [233].
Pameijer et al. [234] reported a local control rate of 78%
for 23 T1 and T2 carcinomas treated with primary radio-
therapy between 1984 and 1993. The local control rate
declinedwhentheapexofthepiriformsinuswasinvolved
by carcinoma and the tumor volume exceeded 6.5 ml. In
a subsequent publication from the same institution, the
5-year local control rate was 90% for T1 tumors and 80%
for T2 tumors. Local control with organ preservation was
86% for patients with T1 tumors and 82% for patients
with T2 carcinomas [235]. Garden et al. [201] achieved
alocalcontrolrateof75.5%in57T1andT2hypopharyn-
geal carcinomas. Wang [202] reported a 5-year local
control rate of 74% for T1 carcinomas and 76% for T2
carcinomas. The 5-year rates for disease-free survival
were 73% for T1 tumors and 68% for T2 tumors. In con-
trast, Jones [236] reported a 5-year disease-specific
survival rate of only 40% for T1 carcinomas and 28% for
T2carcinomas.In2006,Nakamuraetal.[203]described
115 patients with T1 and T2 piriform sinus carcinomas
treated with primary radiotherapy at different Japanese
hospitals. The local control rate was 77% for T1 and 63%
for T2 carcinomas with an overall 5-year disease-specific
survival rate of 77%. Rabbani et al. [237] and Yoshimura
et al. [204] treated 26 and 77 patients with early hypo-
pharyngeal carcinomas and achieved a local control rate
of 86% and 70%, and a 5-year disease-specific survival
rate of 85% and 74%, respectively.
Radiotherapy is generally combined with chemotherapy
inpatientswithlocallyadvancedcarcinomasofthehypo-
pharynx (stage III, IVa). However, chemoradiotherapy has
only slightly improved survival rates. Recent data has
shownthatconcomitantchemoradiotherapyhasadvant-
ages over other chemoradiation protocols with respect
tolocoregionalcontrol[238],[239],[240],butatthecost
of higher toxicity [218], [232], [241].
About50%ofpatientswithlocallyadvancedhypopharyn-
geal carcinomas develop local recurrences after primary
(chemo)-radiotherapy and the 5-year survival rate aver-
agesbetween5%–30%[199],[202],[236],[242],[243],
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demonstrated, that in about 30% of patients severe
functionaldisabilitiesresult.Particularlyswallowingdiffi-
cultiescausedbyimpairedmotility,stricturesofthehypo-
pharynxorupperesophagus,areobservedassideeffects
of chemoradiation [246], [247], [248], [249].
Theresultsofsalvagetreatmentafter(chemo-)radiother-
apy are poor [201], [250], [251], [252], [253] and many
of those patients do not qualify for surgery. In a report by
Taki et al. [254] only 12 out of 41 patients with a recur-
rencecouldundergosurgery.Inonly7casessurgerywas
successful. The risk of pharyngocutaneous fistulas in
secondary laryngectomy is increased if surgery must be
performed within the first couple of months after radio-
therapy.Radiationdosesofover64Grayandconcomitant
chemoradiotherapy increase the risk of pharyngocu-
taneous fistulas [233], [254].
Anothernonsurgicalorgan-preservationapproachinhead
and neck cancer is neoadjuvant chemotherapy with cis-
platin and 5-fluorouracil combined with radiotherapy. A
review of clinical trials conducted between 1970 and
1995 and a meta-analysis of previously published data
shownoclearevidenceforanimprovementinlocoregion-
al tumor control or survival rates or a decrease in the in-
cidence of metachronous distant metastases [255],
[256].Nevertheless,inductionchemotherapyhasbecome
awidelyacceptedtreatmentmodalityforadvancedhead
and neck cancers, particularly in the USA [255], [257].
ArandomizedphaseIIIstudyforhypopharynxcarcinomas
was conducted by the European Organization for Re-
search and Treatment of Cancer (EORTC 24891) [258].
In two arms, induction chemotherapy followed by radio-
therapy was compared with primary laryngopharyngec-
tomy followed by postoperative radiotherapy. In the
“chemotherapy” arm (n=100 patients), 54% of patients
had complete remission at the primary site and 51% at
the regional lymphatics, Patients who did not respond to
chemotherapy underwent surgery (total laryngectomy
withpartialpharyngectomy)andpostoperativeirradiation.
Patients who developed a tumor recurrence following
chemotherapy and irradiation also underwent surgery.
No differences were found between the two treatment
arms with respect to local and regional tumor control.
The 5-year disease-specific survival rate was 29% in the
“chemotherapy” arm and 36% in the “surgery” arm. The
likelihood of being alive with a functional larynx 5 years
after treatment was 35%. This figure was corrected to
22% after final analysis of the study [216].
The authors conclude from their results that induction
chemotherapy followed by radiotherapy can be used for
organ preservation in cancer of the hypopharynx without
compromising survival. A critical analysis of the study,
however, shows that for various reasons only 52 out of
100 patients completed their chemotherapy cycles ac-
cording to the study protocol. This resulted in a relatively
smallnumberforthedefinitiveevaluation.Thecomplica-
tion rate, including two treatment-related deaths, was
remarkably high. While 94% of the patients had stage III
or IV disease, 38 patients had T2 primary tumors with
intact vocal cord mobility. These patients most probably,
could have been treated with organ-preserving surgery.
“Needing radical surgery” appears to have been a rather
subjective inclusion criterion.
InasubsequentphaseIIIstudy(EORTC24954)induction
chemotherapy followed by radiotherapy (n=224) was
comparedwithsimultaneouschemoradiotherapy(n=226)
in patients with resectable larynx carcinomas (T3/T4N0-
N2)orwithhypopharynxcarcinomas(T2-T4N0-N2)[259].
Nosignificantdifferencescouldbeshownbetweenthese
two therapy arms with respect to organ preservation,
overall survival, and toxicity.
A study of the University of Michigan examined the effic-
acy of neoadjuvant chemotherapy with carboplatin and
5-fluorouracilfollowedbyradiotherapyin55patientswith
oropharyngeal cancer and 34 patients with hypopharyn-
geal cancer (stages II-IV) [260]. In 59% of patients with
hypopharyngealcancerlarynxpreservationwasachieved
at the end of treatment. At the time the study was evalu-
ated finally, 29% of the patients with hypopharyngeal
cancer were still alive with a functional larynx and the
5-yearsurvivalratewas24%.Itshouldalsobenotedthat
26%ofpatientsincludedinthetrialhadT1orT2primary
tumors and presumably would have been candidates for
organ-preserving surgery.
Another approach involves modifications of induction
chemotherapy and of fractionating radiotherapy. In a
phaseIIstudyinductionchemotherapywithpaclitaxel/cis-
platin followed by accelerated and hyperfractionated
(concomitant boost) radiotherapy was performed in pa-
tientswithlarynxorhypopharynxcancerwhohadrespon-
ded to chemotherapy [261]. The 3-year survival rate with
preserved and functional larynx was 43% with tolerable
late toxicity.
5.4 Conclusion
In summary, the data show that primary radiotherapy of
“low-volume” T1 and T2 carcinomas of the hypopharynx
is associated with good local control rates. Definitive ra-
diotherapy in “high-volume” T2, T3, and T4 carcinomas
increasesboththelikelihoodforlocalrecurrenceandthe
risk of severe swallowing disorders.
Favorable local control rates were also reported for
supracricoid or supraglottic hemilaryngopharyngectomy
in selected T1, T2, and T3 carcinomas. However, high
morbidity caused by the surgical procedure itself and
preliminary induction chemotherapy, which is obligatory
in some centers, have to be taken into account. With
transorallasermicrosurgerycombinedwithselectiveneck
dissection and adjuvant radiotherapy complication rates
areconsiderablylowercomparedtoopenpartiallaryngo-
pharyngectomy. No lethal complications were reported
followinglasermicrosurgery.Postoperativemorbiditywas
significantly lower, and the 5-year recurrence-free and
overall survival rates significantly higher. Furthermore,
transoral laser microsurgery has a much wider spectrum
ofindicationsthansupracricoidorsupraglottichemilaryn-
gopharyngectomy.
21/31 GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2011, Vol. 10, ISSN 1865-1011
Ambrosch et al.: Functional organ preservation in laryngeal and hypopharyngeal ...With transoral laser microsurgery very favorable local
control rates were achieved in T1 and T2 carcinomas.
The tumor volume has no influence on local control in
contrast to primary radiotherapy. Morbidity and compli-
cation rates are lower than with open surgery or with ra-
diotherapy.Bothopenpartiallaryngopharyngectomyand
transorallasermicrosurgeryaresuperiortoprimaryradio-
therapy with respect to larynx preservation. In case of
pathohistologically uninvolved lymph nodes, adjuvant
radiotherapy is not needed. Generally, transoral laser
microsurgery is suitable for T3 carcinomas with intact
vocalcordmobilityandforselectedcaseswithvocalcord
fixation. Tumor infiltration into adjacent organs, such as
the oropharynx, is not regarded to be a contraindication
for transoral laser microsurgery.
According to the current literature, preservation of a
functional larynx can be achieved in one third of cases
treated with induction chemotherapy followed by radio-
therapy. Results for modified chemotherapy and radio-
therapy protocols have yet to be expected.
Patientsinwhomtransorallasermicrosurgeryisnolonger
possible, and who foreseeable have a high risk for recur-
rence or functional impairment with primary chemoradi-
ation, should better be treated surgically with total laryn-
gectomy,partialpharyngectomyandpostoperativeradio-
therapy.
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